gonadotropin, chorionic
CHORIONIC GONADOTROPIN (gonadotropin, chorionic) is clinical pharmacology: the action of hcg is virtually identical to that of pituitary lh, although hcg appears to have a small degree of fsh activity as well. First approved in 1974.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
Chorionic gonadotropin (hCG) is a hormone replacement injectable that mimics luteinizing hormone (LH) to stimulate gonadal steroid production. It is used to treat infertility, hypogonadism, and cryptorchidism by stimulating testosterone production in males and progesterone in females. The drug works by binding to LH receptors on Leydig cells and corpus luteum to drive hormone synthesis.
Mature product with declining claim volume signals small team focus on retention and cost management rather than growth initiatives.
CLINICAL PHARMACOLOGY: The action of HCG is virtually identical to that of pituitary LH, although HCG appears to have a small degree of FSH activity as well. It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparative Bioavailability Study of Human Chorionic Gonadotropin (hCG)-IBSA Versus a Marketed hCG Formulation
A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation
Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles
HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLimited job openings linked to this product reflect its mature, niche market position. Career opportunities are concentrated in medical affairs, regulatory, and product management for specialty fertility and endocrinology teams.